Dubai, UAE: For a growing number of students today, university is no longer just about lectures, exams, and placements. It is increasingly becoming a space to experiment, build, and sometimes even launch a business before graduation.
(L–R) Prof. Souri Banerjee, Director, BITS Pilani Dubai Campus_ and Prof. Vilas H. Gaidhane, Faculty In-Charge, CIIED, BITS Pilani Dubai Campus
New research highlights visibility gaps around AI-driven identities, rising NHI risks, and an AI security confidence paradox
Dubai, United Arab Emirates – March 25, 2026 —Delinea, a pioneering provider of solutions for securing human and machine identities through centralized authorization, has published new research examining how rapid AI adoption is reshaping identity security risks for enterprises. According to the report, “Uncovering the Hidden Risks of the AI Race,” 90% of organizations pressure security teams to loosen identity controls to enable AI initiatives, despite significant gaps in AI identity discovery, monitoring, and privilege control. The report also reveals an AI security confidence paradox between organizations’ perceived readiness for AI and their actual capabilities to adopt it securely.
Amirah Developments Reflects on 2025 as a Year of Discipline, Trust, and Sustainable Growth
Strategic launches, steady sales progress, and strengthened partnerships position the developer for long-term expansion in Dubai’s evolving real estate market
Date: March 25, 2026; Dubai, UAE
As Dubai’s real estate sector continues to evolve into a more mature and end-user-driven market, Amirah Developments is reflecting on 2025 as a defining year that reinforced the company’s core philosophy of disciplined growth, transparent communication, and long-term value creation.
Over the past year, Dubai’s property market recorded remarkable activity, with total real estate transactions surpassing Dh893 billion, according to the Dubai Land Department. While these numbers highlight the scale of the market’s growth, they also reveal a deeper shift in buyer behaviour. Investors and homeowners alike are becoming increasingly selective, prioritising credibility, thoughtful design, and developers with a clear track record of delivery.
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3
In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss
Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026
INDIANAPOLIS, March 24, 2026 — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight.1,2 The results were published today in The Lancet.
UAE, March 24, 2026 – The Mate series once represented the pinnacle of smartphone innovation. Now, the series returns to the global stage after a brief hiatus. Building on the Mate series’ strong tradition of pioneering technology, the Mate 80 Pro sets new standards in imaging authenticity, durability, performance, and intelligence. At a time when innovation among standard slab smartphones appears to have stalled, the Mate 80 Pro emerges as a serious contender for the best flagship smartphone of the year.